Skip to main content
Triangle logo TriangleGet started

DA-EPOCH (NCT04002947)

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma: a one-minute explainerNCT040029471 min

DA-EPOCH trial for Non-Hodgkin's Lymphoma (NCT04002947). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated stage II–IV diffuse large B-cell or qualifying high-grade B-cell lymphoma, without central nervous system involvement.

The idea: test acalabrutinib, which blocks BTK growth signaling, for 14 days. Patients then receive R-CHOP or DA-EPOCH-R. Only those with at least 25% tumor reduction continue acalabrutinib with chemotherapy; early progression triggers immediate chemotherapy. Treatment uses six cycles.

This phase 2 study plans 132 patients. Christopher Melani leads at the NIH Clinical Center in Bethesda, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.